An open-label, 12 months safety and efficacy study of Levodopa- carbidopa intestinal gel in levodopa-responsive subjects with advanced parkinson's disease and severe motor-fluctuations despite optimized treatment with available parkinson's disease medications
ID Number 09-2309Principal Investigator(s)
Department(s) or Division(s)
The purpose of this study is to find out how well an experimental drug gel and delivery system works as treatment of Parkinson's Disease and how safe it is when taken for 12 months.
Joan Bratton, Study Coordinator
Recruiting Patients: No